Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MRGPRX4 | Q96LA9 | 2/20 | 0.54 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.51 |
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | PPARG | P37231 | 1/20 | 0.51 |
| ▸ | NCOA2 | Q15596 | 1/20 | 0.51 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.51 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 4/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | ATM | Q13315 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 4/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | NPC1 | O15118 | 2/20 | 0.45 |
| ▸ | RAB9A | P51151 | 2/20 | 0.45 |
| ▸ | HTT | P42858 | 2/20 | 0.45 |
| ▸ | PARP1 | P09874 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11984343 | 0.83 | HPGD (0.56) | MRGPRX4NPSR1LMNAPPARGNCOA2 | |
| SCHEMBL1401544 | 0.83 | LMNA (0.53) | MRGPRX4NPSR1LMNAPPARGNCOA2 | |
| SCHEMBL8247469 | 0.82 | MRGPRX4 (0.51) | MRGPRX4NPSR1LMNAPPARGNCOA2 | |
| SCHEMBL6814615 | 0.82 | HDAC3 (0.55) | NPSR1HPGDL3MBTL1TSHRMAPK1 | |
| SCHEMBL1977403 | 0.81 | NPSR1 (0.51) | MRGPRX4NPSR1LMNAPPARGNCOA2 | |
| SCHEMBL28857673 | 0.81 | LMNA (0.51) | MRGPRX4NPSR1LMNAPPARGNCOA2 | |
| SCHEMBL14114132 | 0.81 | LMNA (0.51) | MRGPRX4NPSR1LMNAPPARGNCOA2 | |
| SCHEMBL348559 | 0.81 | LMNA (0.51) | MRGPRX4NPSR1LMNAPPARGNCOA2 | |
| SCHEMBL14135378 | 0.81 | LMNA (0.51) | MRGPRX4NPSR1LMNAPPARGNCOA2 | |
| SCHEMBL16812822 | 0.81 | MRGPRX4 (0.57) | MRGPRX4NPSR1LMNAPPARGNCOA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 110 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4204808-A1 | TARGET ENGAGEMENT ASSAY FOR RAS PROTEINS | Promega Corporation (US) | 2023-07-05 | — | — | EP | disclosed |
| CN-116391129-A | Target binding assays for RAS proteins | 普罗美加公司 | 2023-07-04 | — | — | CN | disclosed |
| US-11649222-B2 | Compounds | UNIVERSITETET I OSLO (NO) | 2023-05-16 | — | — | US | disclosed |
| US-11649222-B2 | Compounds | UNIVERSITETET I OSLO (NO) | 2023-05-16 | — | — | US | disclosed |
| US-11649222-B2 | Compounds | UNIVERSITETET I OSLO (NO) | 2023-05-16 | — | — | US | disclosed |
| CN-115160269-A | Arylcarboxamide derivatives as positive allosteric modulators of NMDAR | 北京大学 | 2022-10-11 | — | — | CN | disclosed |
| EP-3440073-B1 | KINASE INHIBITORS | OXULAR ACQUISITIONS LTD (GB) | 2022-06-08 | — | — | EP | disclosed |
| EP-3978488-A1 | ZINC CHELATING COMPOUNDS FOR USE IN THE TREATMENT OF BACTERIAL INFECTION | Universitetet I Oslo (NO) | 2022-04-06 | — | — | EP | disclosed |
| EP-3978488-A1 | ZINC CHELATING COMPOUNDS FOR USE IN THE TREATMENT OF BACTERIAL INFECTION | Universitetet I Oslo (NO) | 2022-04-06 | — | — | EP | disclosed |
| US-20220064696-A1 | TARGET ENGAGEMENT ASSAY FOR RAS PROTEINS | PROMEGA CORPORATION (US) | 2022-03-03 | — | — | US | disclosed |
| US-20070265321-A1 | THERAPEUTIC COMPOUNDS | ALLERGAN, INC. | 2007-11-15 | — | — | US | disclosed |
| US-20070265321-A1 | THERAPEUTIC COMPOUNDS | ALLERGAN, INC. | 2007-11-15 | — | — | US | disclosed |
| US-20070265321-A1 | THERAPEUTIC COMPOUNDS | ALLERGAN, INC. | 2007-11-15 | — | — | US | disclosed |
| US-20070265330-A1 | SUBSTITUTED GAMMA LACTAMS AS THERAPEUTIC AGENTS | OLD DAVID W | 2007-11-15 | — | — | US | disclosed |
| CN-101068803-A | Biaryloxymethylarene carboxylic acid compounds | HOFFMANN LA ROCHE (CH) | 2007-11-07 | — | — | CN | disclosed |
| US-20070203222-A1 | SUBSTITUTED GAMMA LACTAMS AS THERAPEUTIC AGENTS | ALLERGAN, INC. | 2007-08-30 | — | — | US | disclosed |
| US-20070203222-A1 | SUBSTITUTED GAMMA LACTAMS AS THERAPEUTIC AGENTS | ALLERGAN, INC. | 2007-08-30 | — | — | US | disclosed |
| WO-2006098918-A2 | SUBSTITUTED GAMMA LACTAMS AS THERAPEUTIC AGENTS | ALLERGAN, INC. (US) | 2006-09-21 | — | — | WO | disclosed |
| CN-1812956-A | Biaryloxymethylarenecarboxylic acids as glycogen synthase activator | HOFFMANN LA ROCHE (CH) | 2006-08-02 | — | — | CN | disclosed |
| WO-2004037808-A1 | 2 - SUBSTITUTED HETEROCYCLIC COMPOUNDS AND ANTITUMOR COMPOSITION COMPRISING THE SAME | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2004-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070203222-A1 | SUBSTITUTED GAMMA LACTAMS AS THERAPEUTIC AGENTS | GLA, GANAB, GGH | MRGPRX4 3386/4885NPSR1 4242/4885LMNA 2995/4885 |
| US-11649222-B2 | Compounds | SLC30A6, SLC39A11, SLC39A3 | MRGPRX4 3689/4885NPSR1 617/4885LMNA 1307/4885 |
| US-20070265321-A1 | THERAPEUTIC COMPOUNDS | ACER2, SLC10A1, ASAH2 | MRGPRX4 589/4885NPSR1 1312/4885LMNA 2284/4885 |
| US-20070265330-A1 | SUBSTITUTED GAMMA LACTAMS AS THERAPEUTIC AGENTS | GLA, GUSB, GANAB | MRGPRX4 2399/4885NPSR1 3279/4885LMNA 2349/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.